About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a Healthcare company based in Freienbach (Switzerland) founded in 1998, and was acquired by Abiogen Pharma in May 2023. EffRx Pharmaceuticals is focused on developing treatments for rare and metabolic diseases. It operates on a HealthTech and Direct-to-Consumer (D2C) model. EffRx Pharmaceuticals has raised $2.27 million across 2 funding rounds from investors including European Union and Abiogen Pharma. EffRx Pharmaceuticals offers products and services including Binosto®, Rare Diseases Portfolio, and Musculoskeletal Treatments. Its focus areas include Pharmaceuticals, Rare Disease Treatments and Musculoskeletal Treatments. Its legal entity is EffRx Pharmaceuticals SA.
Company details
EffRx Pharmaceuticals is engaged in the late-stage development and commercialization of prescription medications. The company targets rare endocrine and metabolic disorders, as well as musculoskeletal diseases. Solutions are provided for conditions such as osteoporosis, adrenal insufficiency, and vitamin D deficiency. Operations are centered in Europe and Switzerland, with a strategic focus on niche therapeutics. Partnerships and in-licensing are utilized to enhance market entry and address unmet medical needs.
- Headquarters Freienbach, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website effrx.com
- Social LinkedIn X Facebook
- Acquired by Abiogen Pharma (May 2023)
- Legal Name Effrx Pharmaceuticals Sa
- Total Equity Funding$2.27M (USD)
in 2 rounds
- Latest Funding Round$2.27M (USD), Series A
Jan 2015
- InvestorsEuropean Union
& 1 more
- Acquired byAbiogen Pharma
(May 2023)
Products & Services of EffRx Pharmaceuticals
EffRx Pharmaceuticals offers a comprehensive portfolio of products and services, including Binosto®, Rare Diseases Portfolio, and Musculoskeletal Treatments.
Buffered solution developed for treating osteoporosis in patients.
Medications provided for rare endocrine and metabolic disorders.
Solutions offered for musculoskeletal conditions and vitamin deficiencies.
Funding Insights of EffRx Pharmaceuticals
EffRx Pharmaceuticals has successfully raised a total of $2.27M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.27 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.27M
- Total Rounds 2
- Last Round Series A — $2.27M
- First Round $7.9M
(Oct 2013)
- Investors Count 1
All 2 funding rounds of EffRx Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2015 | $2.27M | Series A | – | – | – |
| Oct 2013 | $7.9M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in EffRx Pharmaceuticals
EffRx Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Abiogen Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Abiogen Pharma is engaged in pharmaceutical development and manufacturing. | 1997 | abiogen.it | Pisa, Italy |
Investor details for EffRx Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EffRx Pharmaceuticals
8 people are tracked at EffRx Pharmaceuticals (5 in leadership, 2 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Lorenzo Bosisio | CEO | Leadership |
Michael Schmid | Director of International Marketing | Leadership |
Paolo Agnoluzzi | CFO | Leadership |
Peter Lichtlen | Chief Medical Advisor | Leadership |
Jérôme Amir | Head Of Accounting | Leadership |
Göran Linder | Board Member | Board & advisors |
Jonas Ekblom | Chairman | Board & advisors |
Victor Papavasileiou | EVP of Corporate Development | Team |
Complete people profiles for EffRx Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EffRx Pharmaceuticals
4 dated milestones of EffRx Pharmaceuticals across 25 years, from founding to its latest funding, stage changes and deals.
- Founded EffRx Pharmaceuticals is founded.
- Funding First funding round of $7.9M.
- Funding Latest funding round, Series A, of $2.3M.
- Exit Acquired by Abiogen Pharma.
Web traffic of EffRx Pharmaceuticals
The website of EffRx Pharmaceuticals (effrx.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▲ 160.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Effrx Pharmaceuticals
Complete news archive for EffRx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EffRx Pharmaceuticals
EffRx Pharmaceuticals was founded in 1998 and raised its 1st funding round 15 years after it was founded.
EffRx Pharmaceuticals is headquartered in Freienbach, Switzerland. It is registered at Freienbach, Schwyz, Switzerland.
EffRx Pharmaceuticals is a funded company, having raised a total of $2.27M across 2 funding rounds to date. The company's 1st funding round was a Grant of $7.9M, raised on Oct 2013.
EffRx Pharmaceuticals is engaged in the late-stage development and commercialization of prescription medications. The company targets rare endocrine and metabolic disorders, as well as musculoskeletal diseases. Solutions are provided for conditions such as osteoporosis, adrenal insufficiency, and vitamin D deficiency. Operations are centered in Europe and Switzerland, with a strategic focus on niche therapeutics. Partnerships and in-licensing are utilized to enhance market entry and address unmet medical needs.
EffRx Pharmaceuticals offers Binosto®, Rare Diseases Portfolio, and Musculoskeletal Treatments.
EffRx Pharmaceuticals has 2 investors. Key investors include European Union, and Abiogen Pharma.
EffRx Pharmaceuticals operates through Effrx Pharmaceuticals Sa.
Yes. EffRx Pharmaceuticals was acquired by Abiogen Pharma in May 2023.